The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
J Clin Psychiatry. 2018 Oct 23;79(6):18m12106. doi: 10.4088/JCP.18m12106.
Studies have identified longitudinally that there exists an association between depression, cerebral blood flow (CBF), and white matter hyperintensities that are thought to be due to vascular pathologies in the brain. However, the changes in CBF, a measure that reflects cerebrovascular integrity, following pharmacotherapy are not well understood. In this study, we investigated the dynamic CBF changes over the course of antidepressant treatment and the association of these changes with depressive symptoms.
We used pseudocontinuous arterial spin labeling to investigate CBF changes in a sample of older patients (≥ 50 years of age; N = 46; 29 female) with a DSM-IV diagnosis of major depressive disorder. Participants had 5 magnetic resonance imaging scans (at baseline, the day after receiving a placebo, the day after receiving a first dose of venlafaxine, a week after starting venlafaxine treatment, and at the end of trial [12 weeks]). Montgomery-Asberg Depression Rating Scale (MADRS) was used to evaluate depression severity and treatment outcome. We investigated the association between changes in depression severity with changes in voxel-wise CBF while adjusting for potential confounding factors.
Increased CBF in the middle and posterior cingulate between baseline and end of treatment was significantly associated with percent decrease in MADRS score, independent of sex and Mini-Mental State Examination score (5,000 permutations, cluster forming threshold P < .005, family-wise error P < .05). No significant effects were detected between baseline and other scans (ie, placebo, acute [single dose], or subacute [after a week]).
Regional CBF increases were associated with decreases in depressive symptoms. This observation is consistent with the vascular depression hypothesis in late-life depression.
ClinicalTrials.gov identifiers: NCT00892047 and NCT01124188.
研究已经确定抑郁、脑血流(CBF)和被认为是由于大脑血管病变引起的脑白质高信号之间存在纵向关联。然而,药物治疗后 CBF 的变化(反映脑血管完整性的指标)尚不清楚。在这项研究中,我们调查了抗抑郁治疗过程中 CBF 的动态变化及其与抑郁症状的关系。
我们使用伪连续动脉自旋标记法(pseudocontinuous arterial spin labeling)来研究一组年龄较大的(≥ 50 岁;N = 46;29 名女性)患有 DSM-IV 诊断为重度抑郁症的患者的 CBF 变化。参与者接受了 5 次磁共振成像扫描(基线时、接受安慰剂后第 1 天、接受文拉法辛第 1 次剂量后第 1 天、开始文拉法辛治疗后第 1 周、试验结束时[12 周])。使用蒙哥马利-阿斯伯格抑郁评定量表(MADRS)评估抑郁严重程度和治疗效果。我们调查了在调整性别和简易精神状态检查(Mini-Mental State Examination)评分等潜在混杂因素后,抑郁严重程度变化与体素 CBF 变化之间的关系。
与基线相比,治疗结束时中后扣带回 CBF 的增加与 MADRS 评分的百分比降低显著相关,独立于性别和简易精神状态检查评分(5000 次随机排列,簇形成阈值 P <.005,全错误率 P <.05)。在基线和其他扫描(即安慰剂、急性[单次剂量]或亚急性[一周后])之间未检测到显著效果。
区域 CBF 的增加与抑郁症状的减轻有关。这一观察结果与老年抑郁症中的血管性抑郁假说一致。
ClinicalTrials.gov 标识符:NCT00892047 和 NCT01124188。